Genetic Technologies’ Digital Strategy Ignites Significant Traction In US Market

Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to report the company's new digital strategy, led by

Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, “Company”, “GTG”)), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to report the company’s new digital strategy, led by the company’s recently appointed strategic advisor, Dr. Malcolm Bohm, is having a significant positive impact across all facets of GTG’s social media platforms.

 

The various analytical markers all showed uplifts, in some cases there was an increase of over 500%.

  • Consumer reach is up 56.3%
  • Content Interactions up 503%
  • Engagement and content views up 175%
  • More than 2,000 fans have joined our page in the last 7 days
  • Website link clicks up 50.8%

     

Digital strategies, such as GTG’s approach, are leveraging the growing awareness of the importance and utility of understanding a person’s individual risk of developing a range of diseases. Know your risk and you and your doctor can take steps to diagnose disease early significantly improving health outcomes.

GTG predicts a significant surge in the adoption of risk assessment tests, driven by both patients and doctors. The company sees its geneType digital strategy as spearheading a transformative shift from “sickcare” to genuine “healthcare”. This transformation is echoed by leading breast specialist, Dr. Nicole Yap, who emphasizes the importance of early detection in breast cancer. Dr. Yap’s sentiments are reinforced by the Australian Breast Care Centre, dedicated to raising awareness about breast cancer risk assessment.

GTG’s approach has garnered substantial interest, evident in the increasing number of healthcare professionals referring patients to their services. Monthly, the company receives commercial samples from new providers across Australia and the US, indicating a growing clinician referral base. In the US, GTG regularly receives samples from over 10 states, with new providers joining each month.

“If you knew you are at moderate to high risk of up to seven potentially fatal cancers, coronary artery disease, atrial fibrillation or type II diabetes you should be very highly motivated to find ways to reduce your risk and prevent disease,” said GTG’s CEO Simon Morriss.

Approved by the Chairman of the Board of Directors.

Total
0
Shares
Related Posts
Read More

Ballard Announces Orders For 70 Hydrogen Fuel Cell Engines For Delivery To Wrightbus In 2024; Expects Delivery Of The Fuel Cell Engines To Occur In 2024, And The Buses To Enter Into Service In 2025, No Financial Terms Disclosed

Ballard Power Systems (NASDAQ:BLDP) (TSX:BLDP) today announced multiple purchase orders totaling 70 FCmove®-HD hydrogen fuel cell engines from its customer Wrightbus (https://wrightbus.com/), a UK-based bus

BLDP

Read More

Wells Fargo Analyst Sees Opportunity For Homebuilding & Building Product Companies Amid Volatility: The Details

Wells Fargo analyst Sam Reid initiated coverage on several homebuilding and building products stocks. The analyst said recent volatility in the homebuilding space offers an opportunity. Reid cites that the high rates pose a barrier for resales but offer interesting TAM implications amid low existing home sales (EHS) builders. 

DHI